Viatris

Viatris has accumulated a pattern of regulatory violations across multiple jurisdictions and domains, indicating systemic compliance failures. In November 2024, the UK Competition and Markets Authority fined the company £1.5 million for failing to comply with a compulsory order during its merger review. In January 2025, the U.S. Food and Drug Administration issued a warning letter to a Viatris plant detailing poor quality control and inadequate handling of manufacturing errors. This followed a significant legal settlement in April 2025, where Viatris agreed to pay up to $335 million over nine years to resolve nationwide opioid-related claims.

According to ViolationTracker, Viatris has been penalized in nine separate enforcement records, with total penalties exceeding $1 billion. While individual penalties may be capped by statute, the recurrence of violations—spanning competition law, drug safety, and public health litigation—demonstrates a repeated failure to meet regulatory standards. This pattern persists alongside significant financial strain, including a credit rating downgrade and high debt, which may pressure operational controls.